-

Evolus to Participate in November Conferences

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November.

Event:

 

Stifel 2022 Healthcare Conference

Date:

 

Tuesday, November 15, 2022

Time:

 

8:35-9:05 am ET

 

Event:

 

5th Annual Evercore ISI HealthCONx Conference

Date:

 

Wednesday, November 30, 2022

Time:

 

11:45-12:05 pm ET

Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com. Replays of the webcasts will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Industry:

EVOLUS, INC.

NASDAQ:EOLS
Details
Headquarters: Newport Beach, CA
CEO: David Moatazedi
Employees: 150
Organization: PUB
Release Summary
Evolus announces that members of its management team will be participating in two investment conferences in November.
Release Versions
English
$Cashtags
$EOLS

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Social Media Profiles
Follow Us on LinkedIn
More News From EVOLUS, INC.

Evolus Announces Commercial Launch of Evolysse™

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for health...

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the launch of its bold new campaign, “Drop the F Word,” ahead of the upcoming commercial launch of Evolysse™. Designed to challenge outdated perceptions and language in the aesthetics industry, the campaign introduces Evolysse™, a collection of injectable hyaluronic acid (HA) gels specifically designed to deliver long-lasting, natural...

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1. The fireside chats can be accessed on the Investor Relations page of the Evolus website here....
Back to Newsroom